Sangamo Therapeutics Reports Officer and Director Changes
Ticker: SGMO · Form: 8-K · Filed: Sep 30, 2025 · CIK: 1001233
| Field | Detail |
|---|---|
| Company | Sangamo Therapeutics, Inc (SGMO) |
| Form Type | 8-K |
| Filed Date | Sep 30, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.01, $347,548, $145,188, $160,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: leadership-change, officer-appointment, director-election
Related Tickers: SGMO
TL;DR
Sangamo's board and execs are changing, effective Sept 24.
AI Summary
Sangamo Therapeutics, Inc. filed an 8-K on September 30, 2025, reporting changes effective September 24, 2025. The filing pertains to the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements for certain officers. Specific details regarding the individuals involved, their roles, and the nature of the compensatory arrangements are not provided in this excerpt.
Why It Matters
Changes in a company's board of directors and executive officers can signal shifts in strategy, governance, or operational focus.
Risk Assessment
Risk Level: medium — Changes in key leadership roles can introduce uncertainty regarding future company direction and performance.
Key Players & Entities
- SANGAMO THERAPEUTICS, INC. (company) — Registrant
- September 24, 2025 (date) — Effective date of reported changes
- September 30, 2025 (date) — Filing date of the 8-K
- 501 Canal Blvd., Richmond, California 94804 (address) — Principal executive offices
FAQ
What specific changes occurred regarding directors or officers at Sangamo Therapeutics?
The 8-K filing indicates the departure of directors or certain officers, the election of directors, and the appointment of certain officers, effective September 24, 2025. However, the specific names and roles are not detailed in this excerpt.
What is the effective date of the reported changes?
The changes reported in the 8-K filing were effective as of September 24, 2025.
When was this 8-K filing submitted to the SEC?
This Form 8-K was filed with the SEC on September 30, 2025.
What is Sangamo Therapeutics' principal executive office address?
Sangamo Therapeutics, Inc.'s principal executive offices are located at 501 Canal Blvd., Richmond, California 94804.
What is the SIC code for Sangamo Therapeutics?
The Standard Industrial Classification (SIC) code for Sangamo Therapeutics is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Stats: 958 words · 4 min read · ~3 pages · Grade level 12.8 · Accepted 2025-09-30 16:01:40
Key Financial Figures
- $0.01 — ange on which registered Common Stock, $0.01 par value per share SGMO Nasdaq Capital
- $347,548 — other things, an annual base salary of $347,548, continued eligibility to receive an an
- $145,188 — other things, an annual base salary of $145,188 and a cash retention bonus of $160,000,
- $160,000 — $145,188 and a cash retention bonus of $160,000, payable on January 31, 2026, subject t
Filing Documents
- sgmo-20250924.htm (8-K) — 31KB
- 0001001233-25-000013.txt ( ) — 145KB
- sgmo-20250924.xsd (EX-101.SCH) — 2KB
- sgmo-20250924_lab.xml (EX-101.LAB) — 21KB
- sgmo-20250924_pre.xml (EX-101.PRE) — 12KB
- sgmo-20250924_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SANGAMO THERAPEUTICS, INC. Dated: September 30, 2025 By: /s/ SCOTT B. WILLOUGHBY Name: Scott B. Willoughby Title: Chief Legal Officer and Corporate Secretary